ACHL

Achilles Therapeutics plc [ACHL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ACHL Stock Summary

Top 10 Correlated ETFs

ACHL

Top 10 Correlated Stocks

ACHL

In the News

ACHL Financial details

Company Rating
-
Market Cap
34.92M
Income
-69.83M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
204
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.5
Forward P/E
-
PEG
1.3
P/S
-
P/B
0.25
P/C
-
P/FCF
-14.72
Quick Ratio
7.71
Current Ratio
8.55
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.75
EPS next Y
-
EPS next Q
-
EPS this Y
-3.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.9%
-
-
-
-
SMA20
20.87%
SMA50
31.13%
SMA100
51.09%
Inst Own
-
Inst Trans
-
ROA
-43%
ROE
-42%
ROC
-0.5%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.74-1.76
52W High
-
52W Low
-
RSI
71.96
Rel Volume
1.18
Avg Volume
800.07K
Volume
948K
Perf Week
0%
Perf Month
15.97%
Perf Quarter
92.44%
Perf Half Y
84.25%
-
-
-
-
Beta
1.087
-
-
Volatility
0%, 0.12%
Prev Close
-0.72%
Price
1.38
Change
-0.72%

Something similar

Top by Market Cap
ABEA.DE
CMC.DE
AMZN
AVGO
AMZ.DE
Top Correlated ETFs
JJCTF
PSIL
JNUG
SGDJ
SGDM
Top Correlated Stocks
PUCK
KAEPF
SKTP
KRBP
LXEH
Similar Market Cap
LKOR
1011.HK
ZVC.TO
KZR
CTUY

Company Profile

Healthcare Biotechnology
  • Volume Average 800.07K
  • Market Capitalization 34.92M
  • Employee 204
  • CEO Dr. Iraj Ali Ph.D.
  • Headquarters London,GB
  • IPO Date 2021-03-31
  • Website https://www.achillestx.com

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.